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Abstract We have recently demonstrated that myocardial
adaptation to ischemia triggers a tyrosine kinase regulated
signaling pathway leading to the translocation and activation of
p38 MAP kinase and MAPKAP kinase 2. Since oxidative stress
is developed during ischemic adaptation and since free radicals
have recently been shown to function as an intracellular signaling
agent leading to the activation of nuclear transcription factor,
NFUB, we examined whether NFUB was involved in the ischemic
adaptation process. Isolated perfused rat hearts were adapted to
ischemic stress by repeated ischemia and reperfusion. Hearts
were pretreated with genistein to block tyrosine kinase while SB
203580 was used to inhibit p38 MAP kinases. Ischemic
adaptation was associated with the nuclear translocation and
activation of NFUB which was significantly blocked by both
genistein and SB 203580. The ischemically adapted hearts were
more resistant to ischemic reperfusion injury as evidenced by
better function recovery and less tissue injury during post-
ischemic reperfusion. Ischemic adaptation developed oxidative
stress which was reflected by increased malonaldehyde forma-
tion. A synthetic peptide containing a cell membrane-permeable
motif and nuclear sequence, SN 50, which blocked nuclear
translocation of NFUB during ischemic adaptation, significantly
inhibited the beneficial effects of adaptation on functional
recovery and tissue injury. In concert, SN 50 reduced the
oxidative stress developed in the adapted myocardium. These
results demonstrate that p38 MAP kinase might be upstream of
NFUB which plays a role in ischemic preconditioning of heart.
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1. Introduction
Mammalian heart can be adapted to ischemia by repeatedly
subjecting it to short-term reversible ischemia each followed
by another short duration of reperfusion [1,2]. This phenom-
enon, known as ischemic adaptation, causes the production of
oxidative stress leading to the induction of gene expression
which is subsequently translated into the development of sev-
eral stress-related proteins responsible for the heart’s defense
[3]. Although the bene¢cial e¡ects of ischemic stress adapta-
tion are well recognized, controversies exist regarding the
mechanism of signal transduction by which ischemic stress
builds up the heart’s defense. Myocardial adaptation to ische-
mia has recently been shown to be mediated through the
activation of tyrosine kinase receptor protein. The signal
transduction process appears to involve tyrosine kinase-
coupled phospholipase D and MAP kinases which lead to
the activation of MAPKAP kinase 2 [4,5]. Our recent study
demonstrated that the ischemic stress speci¢cally translocates
and activates p38 MAP kinases which directly activate MAP-
KAP kinase 2 [6].
The nuclear factor UB (NFUB) appears to be a critical reg-
ulator for gene expression induced by diverse stress signals
including mutagenic, oxidative and hypoxic stresses. NFUB
is a ubiquitous transcription factor which is translocated in
response to oxidative stress from its inactive cytoplasmic form
by releasing the inhibitory subunit IUB from NFUB [7,8]. Ac-
tivation of NFUB is likely to be involved in the induction of
gene expression associated with the ischemic adaptation, since
this transcription factor has recently been found to play a
crucial role in the regulation of ischemia/reperfusion-mediated
gene expression [9].
Substantial evidence exists to support the notion that oxy-
gen-derived free radicals are generated during the reperfusion
of ischemic myocardium resulting in the development of oxi-
dative stress [10,11]. We speculated that ischemia/reperfusion-
induced oxidative stress could cause translocation of NFUB
which might be involved in the regulation of the activation of
MAP kinases observed in conjunction with myocardial stress
adaptation. To examine the role of NFUB in tyrosine kinase
signaling during myocardial adaptation to ischemia, isolated
rat hearts were adapted to ischemic stress by repeated ische-
mia and reperfusion [12]. The adapted heart resulted in the
nuclear translocation and activation of NFUB which was com-
pletely blocked either by inhibiting tyrosine kinase phospho-
rylation or by inhibiting p38 MAP kinase activation. Bene¢-
cial e¡ects of ischemic adaptation were blocked by pretreating
the hearts with a NFUB inhibitor, SN 50 peptide. These
results suggest that NFUB, situated downstream of p38
MAP kinase, plays a crucial role in myocardial adaptation
to ischemia.
2. Materials and methods
2.1. Chemicals
Genistein and SN 50 peptide were purchased from Research Bio-
chemicals, Natick, MA and Calbiochem, CA, respectively. SB 203580
was a gift from the SmithKline and French Laboratories, Philadel-
phia, PA. P65 antibody was purchased from Santa Cruz Biotechno-
logical Co., CA. All other chemicals were of high purity and obtained
from Sigma Chemical Co., St. Louis, MO.
2.2. Isolated perfused heart preparation
Fifty-four Sprague Dawley rats weighing about 300 g were anes-
thetized with pentobarbital (80 mg/kg, i.p.). After intravenous admin-
istration of heparin (500 IU/kg), the chests were opened, the hearts
were rapidly excised and mounted on a non-recirculating Langendor¡
perfusion apparatus [13]. Retrograde perfusion was established at a
pressure of 100 cm H2O with an oxygenated normothermic Krebs-
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Henseleit bicarbonate (KHB) bu¡er with the following ion concentra-
tions (in mM): 118.0 NaCl, 24.0 NaHCO3, 4.7 KCl, 1.2 KH2PO4,
1.2 MgSO4, 1.7 CaCl2, and 10.0 glucose. The KHB bu¡er had been
previously equilibrated with 95% O2/5% CO2, pH 7.4 at 37‡C. To
examine nuclear translocation of NFUB, the hearts were randomly
divided into ¢ve groups. Isolated hearts were perfused with: KHB
bu¡er for 75 min (group I); KHB bu¡er for 15 min for stabilization
followed by 5 min ischemia and 10 min reperfusion (group II); KHB
bu¡er for 15 min in the absence (group III) or presence of 5 WM SB
203580 (group IV) or 100 WM genistein (group V) and then subjected
to ischemic stress adaptation by repeated ischemia and reperfusion by
inducing global ischemia for 5 min followed by 10 min of reperfusion,
repeating the process four times as described previously [12,13]. A
schematic diagram of the protocol is shown in Fig. 1. Another three
groups of hearts were studied to examine the e¡ects on NFUB inhib-
ition on post-ischemic myocardial functions. For this, isolated per-
fused rat hearts were perfused with KHB bu¡er for 75 min followed
by 15 min of ischemia and 2 h of reperfusion (group VI). Another two
groups of hearts were perfused for 15 min with bu¡er in the absence
(group VII) or presence (group VIII) of 18 WM SN 50 peptide, and
then subjected to ischemic stress adaptation as described for group
III. Hearts were then made globally ischemic for 15 min followed by
2 h of reperfusion. A group of four hearts were perfused with 18 WM
SN 50 peptide only for 3.5 h to examine whether SN 50 peptide by
itself had any e¡ects on myocardial function. For NFUB binding
activity (groups I^V), left ventricles from the control and experimental
hearts were kept frozen at liquid nitrogen temperature. Myocardial
functions, creatine kinase (CK) release and malonaldehyde (MDA)
formation were determined in the hearts from groups VI^VIII as
described below.
2.3. Evaluation of myocardial functions
To evaluate myocardial performance, the Langendor¡ preparation
was switched to the working mode following the preconditioning pro-
tocol [13]. Control experiments were performed without subjecting the
hearts to preconditioning. Aortic £ow was measured by a calibrated
rotameter. Coronary £ow rate was measured by a timed collection of
the coronary perfusate that dripped from the heart. After a 10-min
aerobic perfusion of the heart, the aortic in£ow line was clamped at a
point close to the origin of the aortic cannula. Reperfusion was ini-
tiated by unclamping the aortic line. Before ischemia and during re-
perfusion, heart rate (H), coronary £ow (CF) and aortic £ow (AF)
rates were registered. Left ventricular developed pressure (LVDP),
which was de¢ned as the di¡erence between LV systolic and end-
diastolic pressure (EDP) and the ¢rst derivative of LVDP (LVdp/
dt), were also recorded.
2.4. Estimation of CK release
CK was quanti¢ed from 0.5 ml of plasma obtained prior to ische-
mic adaptation and at 30 min, 60 min and 120 min during reperfu-
sion. CK was analyzed by the enzymatic assay method using a CK
assay kit (Sigma Diagnostics, St. Louis, MO). The absorbance was
read at 340 nm using a Beckman DU-8 spectrophotometer.
2.5. Measurement of MDA formation in heart
MDA was estimated in heart muscle to determine the development
of oxidative stress and free radical generation as described previously
[14]. In short, weighed heart biopsies were homogenized in 2 ml of
20% trichloroacetic acid, 5.3 mM sodium bisul¢te, kept on ice for 10
min, centrifuged at 3000Ug for 10 min, and then supernatants were
collected, derivatized with 2,4-dinitrophenylhydrazine (DNPH), and
extracted with pentane. Aliquots of 25 Wl in acetonitrile were injected
onto a Beckman Ultrasphere C18 (3 mm) column. The products were
eluted isocratically with a mobile phase containing acetonitrile-water-
acetic acid (40:60:0.1, v/v) and measured at three di¡erent wave-
lengths (307 nm, 325 nm and 356 nm) using a Waters M-490 multi-
channel UV detector. The peak for malonaldehyde was identi¢ed by
co-chromatography with DNPH derivative of the authentic standard,
peak addition, UV pattern of absorption at the three wavelengths,
and by GC-MS.
2.6. Isolation of nuclear proteins
Nuclear proteins were isolated from the heart according to the
method described previously by Schreiber et al. [15] with slight mod-
i¢cation. In short, about 150 mg of left ventricle from heart tissue was
homogenized in ice-cold Tris-bu¡ered saline (TBS) and centrifuged at
3000Ug for 5 min at 4‡C. The pellet was resuspended by gentle
pipetting in 1.5 ml of ice-cold hypotonic bu¡er containing 10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, 0.5 mM PMSF, and 1 WM each of aprotinin, pepstatin
and leupeptin. The solution was allowed to swell on ice for 15 min.
After addition of 100 Wl of 10% Nonidet P-40, the tube was vigorously
vortexed for 45 s. This homogenate was centrifuged for 30 s at 4‡C in
a microcentrifuge tube. The supernatant contained the cytoplasmic
protein.
The nuclear pellet was resuspended in a solution containing 20 mM
HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 1 mM PMSF and 1 WM each of aprotinin, pepstatin and leu-
peptin. The tubes were vigorously shaken at 4‡C for 30 min on a
shaking platform. The extracts were then centrifuged and the super-
natants were stored at 370‡C. Protein concentration was estimated
using a Pierce protein assay kit (Pierce Chemical Co., Rockford, IL).
2.7. Electrophoretic mobility assay (EMSA)
NFUB oligonucleotide (AGTTGAGGGGACTTTCCCAGG) (2.5
Wl, 20 ng/Wl) was labeled using T4 polynucleotide kinase as previously
described [16]. The binding reaction mixture contained in a total vol-
ume of 20.2 Wl, 0.2 Wl DTT (0.2 M), 1 Wl BSA (20 mg/ml), 4 Wl PdI-dC
(0.5 Wg/Wl), 2 Wl bu¡er D, 4 Wl bu¡er F, 2 Wl 32P-oligo (0.5 ng/Wl) and
7 Wl extract containing 10 Wg protein. Composition of bu¡er D was
20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 0.5 mM EDTA,
0.25% NP 40 while bu¡er F contained 20% Ficoll 400, 100 mM
HEPES, pH 7.9, and 300 mM KCl. Incubation was carried out for
20 min at room temperature. 10 Wl of the solution was loaded onto a
4% acrylamide gel and separated at 80 V until the dye hit the bottom.
After electrophoresis, gels were dried and exposed to Kodak X-ray
¢lm at 370‡C.
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Table 1
E¡ects of SN 50 on myocardial functions
Heart rate
(beats/min)
Developed pressure
(mm Hg)
dp/dtmax
(mm Hg/s)
Aortic £ow
(ml/min)
Coronary £ow
(ml/min)
Infarct size
(%)
Control Baseline 305 þ 3.2 73 þ 1.5 2983 þ 74 43.5 þ 0.9 24.1 þ 0.6 ^
R30 312 þ 7.9 67 þ 6.5 2618 þ 261 30.3 þ 2.22 23.2 þ 1.5
R60 304 þ 11.8 47.1 þ 2.02 2018 þ 268 24.3 þ 3.22 23.2 þ 1.4
R120 295 þ 4.7 35.4 þ 1.82 1520 þ 632 14.4 þ 0.72 18.1 þ 0.42 35 þ 3.2
Adapted Baseline 294 þ 4.9 74 þ 3.1 3064 þ 111 44.0 þ 0.9 24.3 þ 0.4 ^
R30 299 þ 6.9 77.1 þ 2.0 2972 þ 125 34.8 þ 1.4 26.5 þ 1.3
R60 299 þ 7.5 74.6 þ 2.5* 2803 þ 99* 33.4 þ 1.2*2 27.1 þ 1.3
R120 285 þ 9.0 45.4 þ 1.4*2 2055 þ 89*2 24.3 þ 1.2*2 20.6 þ 0.32 17.5 þ 1.7*
SN 50 Baseline 311 þ 8.3 78 þ 3.2 3297 þ 163 42.2 þ 0.6 24.7 þ 1.3 ^
R30 301 þ 4.7 55 þ 4.0** 2219 þ 135** 18.8 þ 2.8**2 24.5 þ 1.3
R60 304 þ 3.8 42 þ 3.6**2 1784 þ 156**2 13.3 þ 2.6**2 27.1 þ 1.3
R120 296 þ 7.4 17 þ 1.1**2 1015 þ 90**2 4.7 þ 0.2**2 25.32 þ 1.9 36.5 þ 4.2**
2P6 0.05 compared to baseline; *P6 0.05 compared to control; **P6 0.05 compared to adapted.
Results are shown as means þ S.E.M. of six rats per group.
R30, R60 and R120: hearts subjected to 30 min ischemia followed by 30, 60 and 120 min reperfusion.
N. Maulik et al./FEBS Letters 429 (1998) 365^369366
2.8. Statistical analysis
For statistical analysis, a two-way analysis of variance (ANOVA)
followed by Sche¡eŁ’s test was ¢rst carried out using Primer Computer
Program (McGraw-Hill, 1988) to test for any di¡erences between
groups. If di¡erences were established, the values were compared us-
ing Student’s t-test for paired data. The values were expressed as
mean þ S.E.M. The results were considered signi¢cant if P was less
than 0.05.
3. Results
3.1. Myocardial adaptation to ischemic stress by repeated
ischemia and reperfusion and its inhibition by SN 50
peptide
As expected, hearts subjected to repeated ischemia and re-
perfusion demonstrated signi¢cantly improved post-ischemic
ventricular recovery as compared to non-adapted hearts. Nei-
ther ischemic adaptation nor SN 50 peptide treatment altered
heart rate during ischemia and reperfusion (Table 1). Aortic
£ow was drastically reduced during reperfusion in both non-
adapted and adapted groups. However, the degree of reduc-
tion was signi¢cantly lower in the adapted group. Coronary
£ow was not a¡ected by ischemic adaptation. For both
groups, the developed pressure (DP) and the ¢rst derivative
of developed pressure (dp/dt) were lower during reperfusion
compared to baseline but these values were signi¢cantly high-
er in the adapted hearts.
Inhibition of NFUB translocation by SN 50 peptide tended
to inhibit the improved myocardial performance a¡orded by
myocardial adaptation to ischemic stress. As shown in Table
1, post-ischemic aortic £ow, DP as well as dp/dt were signi¢-
cantly lower in the SN 50 peptide group as compared to those
in the ischemically stress-adapted group suggesting that NFUB
plays a signi¢cant role in myocardial adaptation to ischemia.
SN 50 peptide by itself had no e¡ects on myocardial perform-
ance or heart rates (results not shown).
3.2. E¡ects of SN 50 peptide on CK release from heart
Release of CK is considered as a presumptive marker for
tissue necrosis and cell death. As shown in Fig. 2, CK release
increased in all the three groups of hearts. However, a slight
increase was noticed in the control heart, and only after 1.5 h
of perfusion with SN 50 peptide. The increase in CK release
from the non-adapted hearts was signi¢cantly higher com-
pared to the ischemically adapted group. Post-ischemic CK
release was signi¢cantly elevated in both ischemically adapted
and SN 50 peptide-treated hearts, but it was signi¢cantly
higher for SN 50 peptide-treated hearts as compared to
adapted hearts suggesting that SN 50 peptide blocked the
bene¢cial e¡ects of ischemic adaptation by increasing tissue
injury. The amount of CK was not a¡ected when hearts were
perfused with SN 50 peptide only for 3.5 h (results not
shown).
3.3. E¡ects of SN 50 peptide on MDA formation in heart
MDA formation truly re£ects the development of oxidative
stress in biological systems. MDA content of heart did not
change even after 3.5 h of perfusion with SN 50 peptide only
(results not shown). In all other groups, MDA increased
steadily and progressively as a function of the reperfusion
time (P6 0.5 compared to baseline, Fig. 3). However, there
were no signi¢cant di¡erences in MDA content of the hearts
between the groups.
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Fig. 2. E¡ects of ischemic adaptation and SN 50 peptide on CK re-
lease from the hearts during post-ischemic reperfusion. Isolated rat
hearts were perfused for 15 min in the absence (stippled bars) or
presence (hatched bars) of 18 WM SN 50 peptide followed by ische-
mic adaptation by repeated ischemia and reperfusion, 15 min global
ischemia (15I) and 120 min of reperfusion (R120). Control experi-
ments were perfusion by perfusing the isolated hearts for 75 min
with KHB bu¡er only followed by 15 min ischemia (15I) and 120
min reperfusion (120R) (black bars). Results are expressed as means
þ S.E.M. of six di¡erent rats per group. *P6 0.05 compared to
baseline; 2P6 0.05 adapted vs. non-adapted control; uP6 0.05 SN
50 peptide vs. adapted.
Fig. 3. E¡ects of ischemic adaptation and SN 50 peptide on MDA
formation in the hearts during post-ischemic reperfusion. Isolated
rat hearts were perfused for 15 min in the absence (stippled bars) or
presence (hatched bars) of 18 WM SN 50 peptide followed by ische-
mic adaptation by repeated ischemia and reperfusion, 15 min global
ischemia (15I) and 120 min of reperfusion (R120). Control experi-
ments were perfusion by perfusing the isolated hearts for 75 min
with KHB bu¡er only followed by 15 min ischemia (15I) and 120
min reperfusion (120R) (black bars). Results are expressed as means
þ S.E.M. of six di¡erent rats per group. *P6 0.05 compared to
baseline; 2P6 0.05 adapted vs. non-adapted control.Fig. 1. Protocol of the experiment.
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3.4. E¡ects of SB 203580 and genistein on the nuclear
translocation of NFUB
NFUB binding activity was found to be very low in non-
ischemic control hearts (Fig. 4, lane A), but it was clearly
detected in the adapted hearts. A signi¢cant increase in
NFUB binding was found in the hearts subjected to once
5 min ischemia followed by 10 min reperfusion (Fig. 4, lane
B). The binding was further increased in the hearts that were
adapted by repeating this adaptation sequence four times
(lane C). As shown in lanes D and E, NFUB binding activity
was signi¢cantly decreased in the hearts pretreated with either
genistein or SB 203580 suggesting that NFUB activation is
regulated by both tyrosine kinase phosphorylation and p38
MAP kinase activity. To con¢rm NFUB binding activity
with p65, we performed supershift assays with polyclonal anti-
bodies recognizing NFUB p65 subunit proteins as shown in
lanes F and G of Fig. 4.
4. Discussion
In this study, we have demonstrated that myocardial adap-
tation to ischemia is associated with the nuclear translocation
and activation of NFUB. Activation of NFUB was blocked by
genistein or SB 203580 indicating that nuclear translocation of
NFUB is regulated by tyrosine kinase phosphorylation and
p38 MAP kinase activation. Inhibition of nuclear transloca-
tion of NFUB by the SN 50 peptide blocked the bene¢cial
e¡ects of ischemic adaptation suggesting that NFUB plays a
role in the intracellular signaling potentiated by ischemic
adaptation.
We have used a synthetic peptide containing a cell mem-
brane-permeable motif and nuclear localization sequence, SN
50, to block the nuclear translocation of NFUB. Such a cell-
permeable peptide import approach was shown to be quite
e¡ective to block nuclear translocation of NFUB in cultured
endothelial and monocyte cells [17]. The authors of this study
clearly showed that cell-permeable SN 50 peptide controlled
signal-transduction-dependent subcellular tra⁄c of transcrip-
tion factors leading to cellular responses to di¡erent agonists
without exerting any cytotoxic e¡ects. The results of our study
also veri¢ed that SN 50 indeed blocked the nuclear translo-
cation of NFUB in the hearts undergoing ischemic adaptation
(results not shown).
Ischemic adaptation may be de¢ned as a phenomenon in
which interruption of brief reversible ischemia by brief reper-
fusion episodes improves myocardial tolerance to subsequent
prolonged ischemia. In fact this has emerged as a state-of-the-
art technique for cardioprotection [1,2,12,18]. Such adaptive
protection is associated with the reduction of cellular energy
demand and anaerobic metabolism during a subsequent peri-
od of sustained ischemia. This technique can delay the onset
of further irreversible injury, reduce subsequent post-ischemic
ventricular dysfunction, decrease the incidence of arrhyth-
mias, and reduce infarct size which makes ischemic adaptation
a potential tool for clinical application [1,2,12,18].
Despite a great deal of research of the preconditioning phe-
nomenon over the last decade, the pathophysiology and the
mechanisms by which preconditioning exerts cardioprotection
remain controversial. It is generally believed that one or more
intracellular mediators rapidly released in response to stress
are responsible for preconditioning. While there is a great deal
of controversy regarding the exact pathway for signal trans-
duction, protein kinase C (PKC) has been implicated as in-
volved in signalling this adaptive response [19]. Recent ¢nd-
ings indicate that multiple kinases including MAP kinases and
MAPKAP kinase 2 are likely to be involved in the precondi-
tioning signaling process [4,5,20]. Additionally, receptor tyro-
sine kinase appears to play a role in transmembrane signaling
of the stress response. This adaptive signal is proposed to be
mediated through a phospholipase D-dependent MAPKAP
kinase 2 pathway [4].
The acutely developing adaptive e¡ect is short-lived, lasting
for only up to 2^3 h. Hearts can subsequently undergo a
secondary and delayed adaptation to stress presumably
through the induction of the expression of new genes and
their subsequent translation into proteins. A number of genes
and proteins have been identi¢ed as possibly involved in the
development of second window or delay preconditioning in-
cluding heat shock proteins, superoxide dismutase, catalase,
nitric oxide synthase as well as ATPase 6 and cytochrome b
subunits [21]. Such an adaptive response becomes evident only
after approximately 24 h of stress treatment and may include
stress induced by heat shock, oxidant or other stress-inducible
agents. MAPKAP kinase 2 appears to link the early precon-
ditioning e¡ect to the delayed adaptive response [4,5].
Recently, oxygen-derived free radicals have been implicated
in transmembrane signaling [22]. In this study, the authors
provided evidence that a tyrosine kinase inhibitor, herbimycin
A, and a free radical scavenger, N-acetylcysteine, inhibit free
radical-induced activation of NFUB indicating that activation
triggered by reactive oxygen species is dependent on tyrosine
kinase activity. The results of our study support this report
and provide further evidence that such signaling also involves
p38 MAP kinase. Activation of MAP kinases by oxygen rad-
icals receives further support from a recent observation where
potent activation of extracellular signal-regulated ERK2 kin-
ase occurred within 10 min of H2O2 treatment [23]. This study
also showed that H2O2 also moderately activated other kin-
ases including p38 MAP kinase. Lipopolysaccharides (LPS),
which can adapt the heart to oxidative stress [24], have been
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Fig. 4. E¡ects of ischemic adaptation on NFUB activity. In non-is-
chemic control hearts there was no translocation of NFUB as can
be seen in lane A. In the ischemically adapted groups, translocations
of NFUB were signi¢cantly increased as noted in lanes B and C.
The binding activities were decreased when genistein or SB 203580
was used to block tyrosine kinase or p38 MAP kinase activity, re-
spectively, as shown in lanes D and E. Supershift assay using poly-
clonal antibody (p65) was performed to verify that these bands were
indeed due to NFUB translocation (lanes F and G).
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found to induce tyrosine phosphorylation of p38 protein [25].
Phosphorylation of p38 was blocked by treatment of cells
with a protein tyrosine kinase inhibitor, herbimycin A, sug-
gesting that tyrosine phosphorylation is involved in LPS-in-
duced oxygen free radical signaling.
Evidence is rapidly accumulating to indicate that oxidative
stress/free radicals lead to the activation of NFUB which in
turn induces the expression of genes [26^28]. Interestingly,
H2O2 was found to activate DNA binding of NFUB in vivo,
but not in vitro [29], suggesting that a byproduct of H2O2 and
not H2O2 by itself may be responsible for the activation of
NFUB. Another related study using transient catalase over-
expression in COS-1 cells showed that H2O2 may not serve
as a messenger for tumor necrosis factor K- or phorbol ester-
induced NFUB activation [30]. It is possible that OHc radical
formed by a transient metal-catalyzed Fenton reaction during
the reperfusion of ischemic heart [31] can induce NFUB acti-
vation. Inhibition of NFkB induction by antioxidants further
supports a role of free radicals in NFUB activation [32].
In summary, to the best of our knowledge, the results of
our study provide evidence for the ¢rst time that the nuclear
transcription factor NFUB is involved in the regulation of
ischemic preconditioning of the heart. The ¢nding that p38
MAP kinase might be upstream of NFUB further supports
our previous reports that MAPKAP kinase 2 could be the
most likely link between the preconditioning and adaptation
mediated by gene expression [33]. p38 activation appears to be
an important step in the translocation and activation of the
nuclear transcription factor NFUB which in turn may be in-
volved the induction of the expression of a variety of stress-
inducible genes [3].
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